A little more than three years ago, a Vanity Fair headline asked the question: “Is Bill Ackman Toast?” At the time, Ackman’s Pershing Square Capital hedge fund firm was sinking under its disastrous bet on Canadian pharmaceuticals rollup Valeant Pharmaceuticals International, its investors